Larson Financial Group’s Olema Pharmaceuticals OLMA Stock Holding History

Larson Financial Group’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$89	Buy	+6	New	+$134	﹤0.01%	3520

Other funds holding OLMA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Larson Financial Group's OLMA Position: Q1 2026 in Review

Larson Financial Group opened a new position in Olema Pharmaceuticals (OLMA) in Q1 2026: 6 shares worth $89. The stake represents ﹤0.01% of the portfolio and ranks #3520 among its holdings.

195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

Larson Financial Group held 6 shares of Olema Pharmaceuticals worth $89 as of Q1 2026.
Olema Pharmaceuticals was a new Larson Financial Group position in Q1 2026.
Olema Pharmaceuticals made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #3520 holding.
195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.